Spontaneous echo-contrast as an in vivo indicator of rheological imbalance in dilatative cardiomyopathy.
The aim of this study was to evaluate coagulative and hemorheologic assessment in patients with dilatative cardiomyopathy with or without spontaneous echo contrast (SEC). We studied 45 patients, 35 males and 10 females (mean age 72.1 +/- 9.2). We measured whole blood viscosity, plasmatic fibrinogen, prothrombin time (PT), activated partial thromboplastin time (aPTT), D-dimer and red cell morphology with Zipursky-Forconi method. Transthoracic and transesophageal echocardiography was performed in all patients to evaluate the presence of SEC in left atrium. We divided all the patients into two groups: the 1st group of 20 patients with SEC and Atrial Fibrillation (AF) in 80% of cases, and the 2nd group of 25 patients without SEC and AF in 31%. Our results show that in patients with SEC there is a statistically significant increase of whole blood viscosity and plasma fibrinogen in comparison with patients without SEC. Red cell morphology in all patients demonstrates a reversed EMI. D-Dimer, was out of the normal range in about 1/3 of the patients in both groups. An analysis of our results points out that in patients with SEC and AF, with a major risk factor for cardioembolic stroke, we have alterations of hemorheologic assessment with an increase of whole blood viscosity and fibrinogen that seems to be caused by an increase of red cells aggregability favoured by fibrinogen. Our conclusions are that SEC in patients with dilatative cardiomyopathy and AF is an important in vivo indicator of hemorheologic imbalance and an important marker for cardioembolic risk stroke evaluation.
Turchetti
V
V
Institute of Internal Medicine and Geriatrics, University of Siena, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy. images@unisi.it
Bellini
M A
MA
Ricci
D
D
Lapi
A
A
Donati
G
G
Boschi
L
L
Trabalzini
L
L
Guerrini
M
M
Forconi
S
S
D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D001809:Blood Viscosity; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use; D017548:Echocardiography, Transesophageal; D004912:Erythrocytes / Q000648:ultrastructure; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006325:Heart Atria / Q000000981:diagnostic imaging / Q000473:pathology; D006400:Hematocrit; D018056:Hemorheology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000453:epidemiology; D013318:Stroke Volume
D002317:Cardiovascular Agents; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen